AI brief of an SEC Form 8-K · Nucor (NUE)

Nucor Q1 2025 profit falls to $156 million, or $0.67 a share, from $845 million a year earlier

Mixed Impact 4 of 5 earnings Written later

Nucor reported first-quarter 2025 net earnings attributable to stockholders of $156 million, or $0.67 per diluted share, down from $845 million, or $3.46 per share, in the first quarter of 2024. Net sales were $7.83 billion, down 4% from a year earlier but up 11% from the fourth quarter of 2024, and the company expects second-quarter 2025 earnings to rise from the first quarter.

Key points

  • Net earnings were $156 million, or $0.67 per diluted share, versus $845 million, or $3.46 per share, in Q1 2024; adjusted earnings were $179 million, or $0.77 per share, excluding $29 million in one-time charges
  • Net sales were $7.83 billion, down 4% year over year and up 11% from the fourth quarter of 2024; average sales price per ton fell 12% year over year
  • Nucor expects second-quarter 2025 earnings to increase versus the first quarter, with the largest increase in the steel mills segment, driven by higher average selling prices at sheet and plate mills
  • The Board declared a $0.55 per share cash dividend payable May 12, 2025; about $806 million remained under the repurchase authorization as of April 5, 2025

The filing

CompanyNucor (NUE)
Form8-K, current report
Filed with the SECApr 28, 2025, 5:00 PM ET
Accession number0001193125-25-100774

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 28, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.